CADM4

Across TCGA pan-cancer cohorts, CADM4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CADM4 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CADM4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CADM4 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

PDAC, GBM, and LSCC are the cancer types where CADM4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.661	1.000	.001	68	view →
GBM	DFS	Median	All	0.846	0.648	.012	7	view →
LSCC	DFS	Quartile	All	0.858	0.543	.008	7	view →
CCRCC	OS	Median	II,III,IV	0.608	0.864	.025	4	view →
HNSC	DFS	Median	All	0.715	0.555	.032	4	view →
LUAD	DFS	Quartile	II,III,IV	0.208	0.726	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CADM4–PDAC (DFS)

Open the PDAC breakdown →